CLINDAMYCIN

Clindamycin Adverse Events Reported to the FDA Over Time

How are Clindamycin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Clindamycin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Clindamycin is flagged as the suspect drug causing the adverse event.

Most Common Clindamycin Adverse Events Reported to the FDA

What are the most common Clindamycin adverse events reported to the FDA?

Diarrhoea	477 (2.05%)
Pyrexia	362 (1.56%)
Rash	340 (1.46%)
Nausea	292 (1.26%)
Dyspnoea	275 (1.18%)
Pruritus	236 (1.01%)
Vomiting	224 (.96%)
Erythema	185 (.8%)
Drug Ineffective	180 (.77%)
Dizziness	170 (.73%)
Drug Interaction	158 (.68%)
	Show More
Renal Failure Acute	156 (.67%)
Headache	154 (.66%)
Drug Hypersensitivity	144 (.62%)
Fatigue	142 (.61%)
Asthenia	140 (.6%)
Abdominal Pain	136 (.58%)
Urticaria	132 (.57%)
Pneumonia	128 (.55%)
Neutropenia	123 (.53%)
Hypotension	121 (.52%)
Ageusia	118 (.51%)
Hypersensitivity	118 (.51%)
Abdominal Pain Upper	113 (.49%)
Chest Pain	113 (.49%)
Chills	112 (.48%)
Pain	112 (.48%)
Clostridium Difficile Colitis	107 (.46%)
Dehydration	104 (.45%)
Sepsis	103 (.44%)
Malaise	102 (.44%)
Pancytopenia	97 (.42%)
Clostridial Infection	96 (.41%)
Drug Rash With Eosinophilia And Sys...	92 (.4%)
Multi-organ Failure	91 (.39%)
Anaemia	90 (.39%)
Aspartate Aminotransferase Increase...	90 (.39%)
Alanine Aminotransferase Increased	88 (.38%)
Swelling Face	88 (.38%)
Infection	87 (.37%)
Thrombocytopenia	86 (.37%)
Liver Disorder	82 (.35%)
Stevens-johnson Syndrome	82 (.35%)
Oedema Peripheral	80 (.34%)
Renal Impairment	80 (.34%)
Toxic Epidermal Necrolysis	80 (.34%)
Condition Aggravated	79 (.34%)
Dysphagia	78 (.34%)
Renal Failure	78 (.34%)
Rash Generalised	77 (.33%)
Tachycardia	75 (.32%)
Drug Eruption	74 (.32%)
Weight Decreased	73 (.31%)
Septic Shock	72 (.31%)
Skin Exfoliation	70 (.3%)
Arthralgia	69 (.3%)
Rash Maculo-papular	69 (.3%)
Cardiac Arrest	67 (.29%)
Loss Of Consciousness	67 (.29%)
Toxic Skin Eruption	67 (.29%)
Burning Sensation	65 (.28%)
Platelet Count Decreased	65 (.28%)
Pseudomembranous Colitis	63 (.27%)
Rash Erythematous	63 (.27%)
Feeling Abnormal	62 (.27%)
Cough	61 (.26%)
Acute Generalised Exanthematous Pus...	60 (.26%)
Interstitial Lung Disease	60 (.26%)
Dysgeusia	59 (.25%)
Febrile Neutropenia	59 (.25%)
Muscle Spasms	59 (.25%)
Blister	57 (.25%)
Confusional State	57 (.25%)
Jaundice	57 (.25%)
Syncope	57 (.25%)
Rash Pruritic	55 (.24%)
Dyspepsia	54 (.23%)
Somnolence	54 (.23%)
White Blood Cell Count Decreased	54 (.23%)
Back Pain	53 (.23%)
Abdominal Distension	52 (.22%)
Haematochezia	52 (.22%)
Hypertension	52 (.22%)
International Normalised Ratio Incr...	52 (.22%)
Hepatic Enzyme Increased	51 (.22%)
Respiratory Failure	51 (.22%)
Haemoglobin Decreased	50 (.21%)
Staphylococcal Infection	50 (.21%)
Death	48 (.21%)
General Physical Health Deteriorati...	48 (.21%)
Urinary Tract Infection	48 (.21%)
Eosinophilia	47 (.2%)
Hepatic Function Abnormal	47 (.2%)
Tremor	47 (.2%)
Atrial Fibrillation	46 (.2%)
Hyperhidrosis	46 (.2%)
Insomnia	46 (.2%)
Tinnitus	46 (.2%)
Anxiety	44 (.19%)
Chest Discomfort	44 (.19%)
Drug Exposure During Pregnancy	44 (.19%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Clindamycin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Clindamycin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Clindamycin

What are the most common Clindamycin adverse events reported to the FDA?

Epidermal And Dermal Conditions	2242 (9.64%)
Gastrointestinal Signs	1161 (4.99%)
Infections - Pathogen Unspecified	1094 (4.7%)
Neurological	989 (4.25%)
Respiratory	819 (3.52%)
Bacterial Infectious	640 (2.75%)
Gastrointestinal Motility And Defec...	631 (2.71%)
Hepatic And Hepatobiliary	517 (2.22%)
Therapeutic And Nontherapeutic Effe...	459 (1.97%)
Hematology Investigations	419 (1.8%)
Renal Disorders	410 (1.76%)
	Show More
Body Temperature Conditions	383 (1.65%)
Hepatobiliary	352 (1.51%)
Allergic Conditions	338 (1.45%)
White Blood Cell	328 (1.41%)
Cardiac Arrhythmias	326 (1.4%)
Lower Respiratory Tract Disorders	290 (1.25%)
Medication Errors	252 (1.08%)
Anemias Nonhemolytic And Marrow Dep...	229 (.98%)
Injuries	229 (.98%)
Electrolyte And Fluid Balance Condi...	216 (.93%)
Musculoskeletal And Connective Tiss...	199 (.86%)
Administration Site Reactions	192 (.83%)
Decreased And Nonspecific Blood Pre...	190 (.82%)
Angiedema And Urticaria	188 (.81%)
Cardiac And Vascular Investigations	188 (.81%)
Fungal Infectious	182 (.78%)
Joint	175 (.75%)
Headaches	173 (.74%)
Skin Appendage Conditions	170 (.73%)
Muscle	169 (.73%)
Oral Soft Tissue Conditions	165 (.71%)
Upper Respiratory Tract Disorders	165 (.71%)
Physical Examination Topics	159 (.68%)
Gastrointestinal Hemorrhages	154 (.66%)
Movement Disorders	146 (.63%)
Gastrointestinal Inflammatory Condi...	141 (.61%)
Urinary Tract Signs	124 (.53%)
Vision	122 (.52%)
Anxiety Disorders	118 (.51%)
Ocular Infections, Irritations And ...	117 (.5%)
Tongue Conditions	116 (.5%)
Enzyme	107 (.46%)
Platelet	105 (.45%)
Chemical Injury And Poisoning	104 (.45%)
Renal And Urinary Tract Investigati...	102 (.44%)
Viral Infectious	101 (.43%)
Procedural And Device Related Injur...	100 (.43%)
Appetite And General Nutritional	95 (.41%)
Eye	95 (.41%)
Deliria	94 (.4%)
Metabolic, Nutritional And Blood Ga...	89 (.38%)
Product Quality Issues	89 (.38%)
Gastrointestinal Conditions	87 (.37%)
Water, Electrolyte And Mineral	85 (.37%)
Hematological And Lymphoid Tissue T...	82 (.35%)
Bone Disorders	80 (.34%)
Skin Vascular Abnormalities	80 (.34%)
Suicidal And Self-injurious Behavio...	80 (.34%)
Dental And Gingival Conditions	79 (.34%)
Gastrointestinal Ulceration And Per...	79 (.34%)
Microbiology And Serology	77 (.33%)
Vascular	77 (.33%)
Central Nervous System Vascular	76 (.33%)
Sleep Disorders	76 (.33%)
Lifestyle Issues	75 (.32%)
Musculoskeletal And Connective Tiss...	75 (.32%)
Seizures	74 (.32%)
Cardiac Disorder Signs	71 (.31%)
Coronary Artery	71 (.31%)
Vulvovaginal Disorders	65 (.28%)
Cranial Nerve Disorders	64 (.28%)
Hearing	64 (.28%)
Coagulopathies And Bleeding Diathes...	63 (.27%)
Disturbances In Thinking	63 (.27%)
Inner Ear And Viiith Cranial Nerve	63 (.27%)
Tissue	62 (.27%)
Fatal Outcomes	61 (.26%)
Heart Failures	61 (.26%)
Acid-base	59 (.25%)
Depressed Mood Disorders	57 (.25%)
Myocardial	57 (.25%)
Embolism And Thrombosis	55 (.24%)
Glucose Metabolism Disorders	55 (.24%)
Vascular Hypertensive	55 (.24%)
Leukemias	53 (.23%)
Cardiac Valve	51 (.22%)
Protein And Chemistry Analyses	51 (.22%)
Mental Impairment	50 (.21%)
Peritoneal And Retroperitoneal Cond...	50 (.21%)
Spleen, Lymphatic And Reticulendoth...	50 (.21%)
Nephropathies	48 (.21%)
Bronchial Disorders	47 (.2%)
Psychiatric	46 (.2%)
Pleural	45 (.19%)
Tendon, Ligament And Cartilage	44 (.19%)
Vascular Hemorrhagic	44 (.19%)
Mood Disorders	43 (.18%)
Injuries By Physical Agents	42 (.18%)
Immune	40 (.17%)
Bone And Joint Injuries	39 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Clindamycin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Clindamycin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.